PT1856045E - Derivados do ácido indol-1-acético que possuem actividade antagonista de pgd2 - Google Patents

Derivados do ácido indol-1-acético que possuem actividade antagonista de pgd2 Download PDF

Info

Publication number: PT1856045E
Authority: PT; Portugal
Prior art keywords: acetic acid; antagonist activity; indole derivatives; alkyl; pgd2
Prior art date: 2005-03-11

Application number

PT06726357T

Other languages

English (en)

Inventor

Richard Edward Armer

Edward Andrew Boyd

Philip Andrew Hay

Original Assignee

Oxagen Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-03-11

Filing date

2006-03-10

Publication date

2009-12-09

2006-03-10 Application filed by Oxagen Ltd filed Critical Oxagen Ltd

2009-12-09 Publication of PT1856045E publication Critical patent/PT1856045E/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Pulmonology (AREA)
Dermatology (AREA)
Rheumatology (AREA)
Cardiology (AREA)
Orthopedic Medicine & Surgery (AREA)
Heart & Thoracic Surgery (AREA)
Vascular Medicine (AREA)
Pain & Pain Management (AREA)
Urology & Nephrology (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Psychology (AREA)
Ophthalmology & Optometry (AREA)
Physical Education & Sports Medicine (AREA)
Transplantation (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Indole Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Plural Heterocyclic Compounds (AREA)

PT06726357T 2005-03-11 2006-03-10 Derivados do ácido indol-1-acético que possuem actividade antagonista de pgd2 PT1856045E (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GBGB0505048.9A GB0505048D0 (en)	2005-03-11	2005-03-11	Compounds with PGD antagonist activity

Publications (1)

Publication Number	Publication Date
PT1856045E true PT1856045E (pt)	2009-12-09

Family

ID=34508918

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PT06726357T PT1856045E (pt)	2005-03-11	2006-03-10	Derivados do ácido indol-1-acético que possuem actividade antagonista de pgd2

Country Status (27)

Country	Link
US (1)	US8044088B2 (pt)
EP (1)	EP1856045B1 (pt)
JP (1)	JP2008532990A (pt)
KR (1)	KR20070116633A (pt)
CN (1)	CN101166721A (pt)
AT (1)	ATE442356T1 (pt)
AU (1)	AU2006221784A1 (pt)
BR (1)	BRPI0608732A2 (pt)
CA (1)	CA2601980A1 (pt)
CY (1)	CY1109532T1 (pt)
DE (1)	DE602006009080D1 (pt)
DK (1)	DK1856045T3 (pt)
ES (1)	ES2333161T3 (pt)
GB (1)	GB0505048D0 (pt)
HK (1)	HK1109628A1 (pt)
HR (1)	HRP20090654T1 (pt)
IL (1)	IL185844A0 (pt)
MX (1)	MX2007011091A (pt)
NO (1)	NO20074641L (pt)
NZ (1)	NZ561747A (pt)
PL (1)	PL1856045T3 (pt)
PT (1)	PT1856045E (pt)
RS (1)	RS51016B (pt)
RU (1)	RU2007134456A (pt)
SI (1)	SI1856045T1 (pt)
WO (1)	WO2006095183A1 (pt)
ZA (1)	ZA200708159B (pt)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0324763D0 (en) *	2003-10-23	2003-11-26	Oxagen Ltd	Use of compounds in therapy
EP2037967B1 (en)	2006-06-16	2016-12-07	The Trustees Of The University Of Pennsylvania	Prostaglandin d2 receptor antagonists for treating androgenetic alopecia
MX2009000801A (es) *	2006-07-22	2009-02-03	Oxagen Ltd	Compuestos que tienen actividad antagonista crth2.
EP2316824A1 (en)	2006-08-07	2011-05-04	Actelion Pharmaceuticals Ltd.	(3-Amino-1,2,3,4-tetrahydro-9H-carbazoI-9-yl)-acetic acid derivates
GB0722203D0 (en) *	2007-11-13	2007-12-19	Oxagen Ltd	Use of CRTH2 antagonist compounds
GB0722216D0 (en) *	2007-11-13	2007-12-27	Oxagen Ltd	Use of crth2 antagonist compounds
ES2386340T3 (es)	2007-12-14	2012-08-17	Pulmagen Therapeutics (Asthma) Limited	Indoles y su uso terapéutico
US7750027B2 (en)	2008-01-18	2010-07-06	Oxagen Limited	Compounds having CRTH2 antagonist activity
WO2009090414A1 (en) *	2008-01-18	2009-07-23	Oxagen Limited	Compounds having crth2 antagonist activity
EP2240444A1 (en) *	2008-01-22	2010-10-20	Oxagen Limited	Compounds having crth2 antagonist activity
US8470594B2 (en) *	2008-04-15	2013-06-25	President And Fellows Of Harvard College	Methods for identifying agents that affect the survival of motor neurons
US9180114B2 (en)	2008-11-26	2015-11-10	President And Fellows Of Harvard College	Neurodegenerative diseases and methods of modeling
PL2401269T3 (pl) *	2009-02-24	2014-07-31	Merck Sharp & Dohme	Pochodne indolu jako antagoniści receptora CRTH2
ES2524079T3 (es)	2010-03-22	2014-12-04	Actelion Pharmaceuticals Ltd.	Derivados de 3-(heteroaril-amino)-1,2,3,4-tetrahidro-9H-carbazol y su uso como moduladores del receptor de prostaglandina D2
GB201103837D0 (en)	2011-03-07	2011-04-20	Oxagen Ltd	Amorphous (5-Fluoro-2-Methyl-3-Quinolin-2-Ylmethyl-Indol-1-Yl)-acetic acid
MX338516B (es)	2011-04-14	2016-04-20	Actelion Pharmaceuticals Ltd	Derivados de acido 7- (heteroaril-amino) -6, 7, 8, 9- tetrahidropirido[1,2-a] indol acetico y sus usos como modulador del receptor de prostaglandina.
DK2781508T3 (en) *	2011-11-17	2019-03-11	Kbp Biosciences Co Ltd	NITROGEN CONCENTRATED RING COMPOUNDS FOR USE AS CRTH2 ANTAGONISTS
GB201121557D0 (en)	2011-12-15	2012-01-25	Oxagen Ltd	Process
CA2859284A1 (en)	2011-12-16	2013-06-20	Atopix Therapeutics Limited	Combination of a crth2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis
EP3382391A1 (en)	2012-10-24	2018-10-03	NYU Winthrop Hospital	Non-invasive biomarker to identify subjects at risk of preterm delivery
KR102116978B1 (ko)	2013-10-07	2020-05-29	삼성전자 주식회사	그래핀 소자 및 그 제조 방법
GB201322273D0 (en)	2013-12-17	2014-01-29	Atopix Therapeutics Ltd	Process
PT3119779T (pt)	2014-03-17	2018-10-19	Idorsia Pharmaceuticals Ltd	Derivados de ácido azaindol acético e sua utilização como modeladores de recetor d2 de prostaglandina
GB201407820D0 (en)	2014-05-02	2014-06-18	Atopix Therapeutics Ltd	Polymorphic form
GB201407807D0 (en) *	2014-05-02	2014-06-18	Atopix Therapeutics Ltd	Polymorphic form
ES2991300T3 (es)	2015-02-13	2024-12-03	Inserm Institut Nat De La Sante Et De Larecherche Medicale	Antagonistas de PTGDR-1 y/o PTGDR-2 para prevenir y/o tratar lupus eritematoso sistémico
BR112018002012A2 (pt)	2015-07-30	2018-09-18	Univ Pennsylvania	alelos polimórficos de nucleotídeo único de gene dp-2 humano para detecção de suscetibilidade à inibição do crescimento de cabelos por pgd2
EP3350179B1 (en)	2015-09-15	2021-01-13	Idorsia Pharmaceuticals Ltd	Crystalline forms
AU2018331400A1 (en)	2017-09-13	2020-04-02	Progenity, Inc.	Preeclampsia biomarkers and related systems and methods
CN109180691B (zh) *	2018-08-24	2020-07-10	武汉大学	一种c3-芳香型吡咯并吲哚类生物碱及其合成方法
EP4070113A4 (en)	2019-12-04	2023-12-20	Biora Therapeutics, Inc.	ASSESSMENT OF PREECAMPSIA USING FREE AND DISSOCIATE PLACENTAL GROWTH FACTOR ASSAYS
CN113425714B (zh) *	2021-08-04	2022-04-26	华南师范大学	吲哚乙酸在制备防治慢性阻塞性肺病药物中的应用
CN114870018A (zh) *	2022-05-12	2022-08-09	江南大学	炎症小体nlrp3抑制剂通过抑制神经系统炎症在制备治疗阿尔茨海默症药物中的应用
WO2024192765A1 (en) *	2023-03-23	2024-09-26	Brown University	First in class use of the crth2 antagonist in treating neuromyelitis optica spectrum disorder (nmosd) and relevant autoimmune cns disorders

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5641800A (en)	1994-07-21	1997-06-24	Eli Lilly And Company	1H-indole-1-functional sPLA2 inhibitors
JP3494990B2 (ja)	1998-03-31	2004-02-09	ザインスティテューツフォアファーマスーティカルディスカヴァリーエルエルシー	置換されたインドールアルカノール酸
WO2003097598A1 (fr) *	2002-05-16	2003-11-27	Shionogi & Co., Ltd.	Composé comprenant un antagonisme du récepteur de pdg2
TW200307542A (en)	2002-05-30	2003-12-16	Astrazeneca Ab	Novel compounds
SE0202241D0 (sv)	2002-07-17	2002-07-17	Astrazeneca Ab	Novel Compounds
SE0302232D0 (sv) *	2003-08-18	2003-08-18	Astrazeneca Ab	Novel Compounds
GB0324763D0 (en)	2003-10-23	2003-11-26	Oxagen Ltd	Use of compounds in therapy
SE0303180D0 (sv)	2003-11-26	2003-11-26	Astrazeneca Ab	Novel compounds
GB0504150D0 (en)	2005-03-01	2005-04-06	Oxagen Ltd	Microcrystalline material
MX2009000801A (es)	2006-07-22	2009-02-03	Oxagen Ltd	Compuestos que tienen actividad antagonista crth2.
ES2386340T3 (es)	2007-12-14	2012-08-17	Pulmagen Therapeutics (Asthma) Limited	Indoles y su uso terapéutico
US7750027B2 (en)	2008-01-18	2010-07-06	Oxagen Limited	Compounds having CRTH2 antagonist activity
EP2240444A1 (en)	2008-01-22	2010-10-20	Oxagen Limited	Compounds having crth2 antagonist activity
US20100022613A1 (en)	2008-01-22	2010-01-28	Oxagen Limited	Compounds Having CRTH2 Antagonist Activity

2005
- 2005-03-11 GB GBGB0505048.9A patent/GB0505048D0/en not_active Ceased
2006
- 2006-03-10 NZ NZ561747A patent/NZ561747A/xx not_active IP Right Cessation
- 2006-03-10 ES ES06726357T patent/ES2333161T3/es active Active
- 2006-03-10 CN CNA2006800139287A patent/CN101166721A/zh active Pending
- 2006-03-10 RU RU2007134456/04A patent/RU2007134456A/ru not_active Application Discontinuation
- 2006-03-10 EP EP06726357A patent/EP1856045B1/en active Active
- 2006-03-10 BR BRPI0608732A patent/BRPI0608732A2/pt not_active IP Right Cessation
- 2006-03-10 KR KR1020077023379A patent/KR20070116633A/ko not_active Application Discontinuation
- 2006-03-10 DK DK06726357T patent/DK1856045T3/da active
- 2006-03-10 RS RSP-2009/0534A patent/RS51016B/sr unknown
- 2006-03-10 US US11/908,401 patent/US8044088B2/en not_active Expired - Fee Related
- 2006-03-10 PL PL06726357T patent/PL1856045T3/pl unknown
- 2006-03-10 MX MX2007011091A patent/MX2007011091A/es active IP Right Grant
- 2006-03-10 CA CA002601980A patent/CA2601980A1/en not_active Abandoned
- 2006-03-10 AT AT06726357T patent/ATE442356T1/de active
- 2006-03-10 SI SI200630491T patent/SI1856045T1/sl unknown
- 2006-03-10 AU AU2006221784A patent/AU2006221784A1/en not_active Withdrawn
- 2006-03-10 JP JP2008500270A patent/JP2008532990A/ja active Pending
- 2006-03-10 WO PCT/GB2006/000851 patent/WO2006095183A1/en active Application Filing
- 2006-03-10 DE DE602006009080T patent/DE602006009080D1/de active Active
- 2006-03-10 PT PT06726357T patent/PT1856045E/pt unknown
2007
- 2007-09-10 IL IL185844A patent/IL185844A0/en unknown
- 2007-09-12 NO NO20074641A patent/NO20074641L/no not_active Application Discontinuation
- 2007-09-21 ZA ZA200708159A patent/ZA200708159B/xx unknown
2008
- 2008-04-08 HK HK08103897.0A patent/HK1109628A1/xx not_active IP Right Cessation
2009
- 2009-12-08 CY CY20091101280T patent/CY1109532T1/el unknown
- 2009-12-09 HR HR20090654T patent/HRP20090654T1/hr unknown

Also Published As

Publication number	Publication date
JP2008532990A (ja)	2008-08-21
HRP20090654T1 (hr)	2010-01-31
CY1109532T1 (el)	2014-08-13
NO20074641L (no)	2007-11-01
DE602006009080D1 (de)	2009-10-22
BRPI0608732A2 (pt)	2016-11-08
MX2007011091A (es)	2007-11-22
GB0505048D0 (en)	2005-04-20
IL185844A0 (en)	2008-01-06
EP1856045B1 (en)	2009-09-09
HK1109628A1 (en)	2008-06-13
RU2007134456A (ru)	2009-04-20
NZ561747A (en)	2010-03-26
CA2601980A1 (en)	2006-09-14
WO2006095183A1 (en)	2006-09-14
EP1856045A1 (en)	2007-11-21
CN101166721A (zh)	2008-04-23
DK1856045T3 (da)	2010-01-04
SI1856045T1 (sl)	2010-01-29
US8044088B2 (en)	2011-10-25
ZA200708159B (en)	2009-11-25
PL1856045T3 (pl)	2010-02-26
ATE442356T1 (de)	2009-09-15
KR20070116633A (ko)	2007-12-10
AU2006221784A1 (en)	2006-09-14
RS51016B (sr)	2010-10-31
US20100330077A1 (en)	2010-12-30
ES2333161T3 (es)	2010-02-17

Publication	Publication Date	Title
HK1109628A1 (en)	2008-06-13	1-acetic acid-indole derivatives with pgd2 antagonist activity
ATE553106T1 (de)	2012-04-15	Heteroarylpyrrolopyridinone als kinaseinhibitoren
HRP20070430T3 (en)	2007-11-30	(3-oxo-3,4-dihydro-quinoxalin-2-yl-amino)-benzamide derivatives and related compounds as glycogen phosphorylase inhibitors for the treatment of diabetes and obesity
NO20071617L (no)	2007-04-20	Indozolonderivater som 11B-HSD1-inhibitorer
NO20070532L (no)	2007-01-29	Substituerte 2-alkyl-kinazolinonderivater som PARP-inhibitorer
MX2009006756A (es)	2009-06-30	Derivados de 1-amino-metil-l-fenil-ciclohexano como inhibidores de dpp-iv.
ATE496620T1 (de)	2011-02-15	1h-benzo(f)indazol-5-yl-derivate als selektive glucocorticoid-rezeptor-modulatoren
TW200637550A (en)	2006-11-01	Thiazole-4-carboxamide derivatives as mGluR5 antagonists
DE602006011752D1 (de)	2010-03-04	Als antikoagulationsmittel geeignete phenylglycinamid- und pyridylglycinamidderivate
GEP20094605B (en)	2009-02-10	Pyrazole derivatives, compositions containing such compounds and methods of use thereof
DE60317326D1 (de)	2007-12-20	Phenylalkansäure- und phenyloxyalkansäure-derivate als hppar aktivatore
TW200716650A (en)	2007-05-01	Thienopyridine derivative, or quinoline derivative, or quinazoline derivative, having c-met autophosphorylation inhibiting potency
GB0510584D0 (en)	2005-06-29	Organic compounds
DK1755590T3 (da)	2011-12-12	Kombination af glycopyrrolat og en beta2-adrenoceptoragonist
UA95972C2 (ru)	2011-09-26	Аминопиридиновые производные с селективной ингибирующей активностью в отношении авроры а
MX2010006882A (es)	2010-10-05	Derivado novedoso de catecol, composición farmaceutica que contiene el mismo, uso del derivado de catecol, y uso de la composición farmaceutica.
AU2003250471A8 (en)	2004-02-25	Pyrimidine-2,4-dione derivatives as matrix metalloproteinase inhibitors
NO20071319L (no)	2007-05-29	Fremgangsmate for fremstilling av isotiazolderivater.
CO6321159A2 (es)	2011-09-20	Compuestos pirazina fusionados utiles para el tratamiento de enfermedades degenerativas e inflamatorias
WO2009028387A1 (ja)	2009-03-05	プロテアーゼ阻害剤耐性を有する癌の治療薬
MX2009004553A (es)	2009-11-10	Metodos para el tratamiento de trastornos cocleares y vestibulares.
WO2005053702A3 (en)	2005-09-15	Anti-inflammatory agents
WO2006029154A3 (en)	2006-11-23	Novel compounds
MY140666A (en)	2010-01-15	Biotinylated hexadecasaccharides, preparation and use thereof
WO2007057571A3 (fr)	2007-07-12	Derives de 3-acylindole, leur preparation et leur application en therapeutique comme modulateurs pour les recepteurs cb2